Abstract
There is a significant heterogeneity among individuals in terms of platelet aggregation response to arginine vasopressin (AVP). The aim of this study was to evaluate whether four single nucleotide polymorphisms (SNPs) in the promoter region of vasopressin V1a receptor gene (V1aR) could be used as genetic markers for divergent platelet aggregation response to AVP. Seventeen of 33 subjects showed more than 60% of maximum platelet aggregation and were classified as responders. Sixteen were classified as nonresponders because they had less than 30% aggregation. In a preliminary study, V1aR gene sequences were determined in two responders and two nonresponders. We found four SNPs in the promoter region of the V1aR gene: –6951G/A, –4112A/T, –3860T/C, and –242C/T. In all 33 subjects the genotypes of four SNPs were determined using either polymerase chain reaction (PCR) with allele‐specific primers or PCR followed by restriction‐fragment length polymorphism (RFLP). There were no differences in the AVP‐induced aggregation between the subjects with and without variant alleles of each four SNPs. The genotype frequencies of four SNPs of V1aR were almost identical between AVP responders and nonresponders. These results suggest that the four SNPs in the promoter region of the V1aR gene may not be useful as genetic markers for platelet aggregation heterogeneity. J. Clin. Lab. Anal. 20:87–92, 2006. © 2006 Wiley‐Liss, Inc.
Keywords: receptors, vasopressin, V1a receptor, SNPs, platelet aggregation heterogeneity
REFERENCES
- 1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes, 1. N Engl J Med 1992; 326:242–250. [DOI] [PubMed] [Google Scholar]
- 2. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983–989. [DOI] [PubMed] [Google Scholar]
- 3. Del Zoppo GJ, Hallenback JM. Advances in the vascular pathophysiology of ischemic stroke. Thromb Res 2000; 98:73–81. [DOI] [PubMed] [Google Scholar]
- 4. Hamet P, Skuherska R, Pang SC, Tremblay J. Abnormalities of platelet function in hypertension and diabetes. Hypertension 1985; 7:II135–142. [DOI] [PubMed] [Google Scholar]
- 5. Kjeldsen SE, Rostrup M, Gjesdal K, Eide I. The epinephrine‐blood platelet connection with special reference to essential hypertension. Am Heart J 1991; 122:330–336. [DOI] [PubMed] [Google Scholar]
- 6. Opper C, Clement C, Schwarz H, et al. Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 1995; 113:211–217. [DOI] [PubMed] [Google Scholar]
- 7. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279:1643–1650. [DOI] [PubMed] [Google Scholar]
- 8. Holmsen H. Physiological functions of platelets. Ann Med 1989; 21:23–30. [DOI] [PubMed] [Google Scholar]
- 9. Jin Y, Dietz HC, Montgomery RA, et al. Glanzmann thrombasthenia: cooperation between sequence variants in cis during splice site selection. J Clin Invest 1996; 98:1745–1754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Bray PF. Inherited diseases of platelet glycoproteins: considerations for rapid molecular characterization. Thromb Haemost 1994; 72:492–502. [PubMed] [Google Scholar]
- 11. Gaxiola B, Friedl W, Propping P. Epinephrine‐induced platelet aggregation: a twin study. Clin Genet 1984; 26:543–548. [DOI] [PubMed] [Google Scholar]
- 12. Propping P, Friedl W. Genetic control of adrenergic receptors on human platelets: a twin study. Hum Genet 1983; 64:105–109. [DOI] [PubMed] [Google Scholar]
- 13. Propping P, Friedl W, Hebebrand J, Lentes KU. Genetic studies at the receptor level: investigations in human twins and experimental animals. Ciba Found Symp 1986; 123:42–56. [DOI] [PubMed] [Google Scholar]
- 14. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the α2 gene define multiple alleles that are associated with differences in platelet α2 β1 density. Blood 1998; 92:2382–2388. [PubMed] [Google Scholar]
- 15. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin α2 β1 density is associated with two silent polymorphisms in the α2 gene coding sequence. Blood 1997; 89:1939–1943. [PubMed] [Google Scholar]
- 16. Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev 1988; 68:1248–1284. [DOI] [PubMed] [Google Scholar]
- 17. Lachant NA, Smith MR, Xie ZJ, Romani WR. Heterogeneity of the aggregation response of human platelets to arginine vasopressin. Am J Hematol 1995; 49:56–66. [DOI] [PubMed] [Google Scholar]
- 18. Thibonnier M, Graves MK, Wagner MS, et al. Study of V1‐vascular vasopressin receptor gene microsatellite polymorphisms in human essential hypertension. J Mol Cell Cardiol 2000; 32:557–564. [DOI] [PubMed] [Google Scholar]
- 19. Saito S, Lida A, Sekine A, et al. Catalog of 178 variations in the Japanese population among eight human genes encoding G protein‐coupled receptors (GPCRs). J Hum Genet 2003; 48:461–468. [DOI] [PubMed] [Google Scholar]
- 20. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000; 11:406–410. [DOI] [PubMed] [Google Scholar]
- 21. Jin J, Kunapuli SP. Coactivation of two different G protein‐coupled receptors is essential for ADP‐induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95:8070–8074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Offermanns S, Toombs CF, Hu YH, Simon MI. Defective platelet activation in Gq‐deficient mice. Nature 1997; 389:183–186. [DOI] [PubMed] [Google Scholar]
- 23. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa P1A2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999; 19:1142–1147. [DOI] [PubMed] [Google Scholar]
- 24. Young LJ, Nilsen R, Waymire KG, MacGregor GR, Insel TR. Increased affiliative response to vasopressin in mice expressing the V1a receptor from a monogamous vole. Nature 1999; 400:766–768. [DOI] [PubMed] [Google Scholar]